Fosfomycin tromethamine is an oral antibiotic best known for treating uncomplicated urinary tract infections with a single dose, a convenience almost no other antibiotic can match. It works through a mechanism unlike any other antibiotic class, maintains activity against many drug-resistant bacteria that have rendered older treatments useless, and has a safety profile gentle enough to use during pregnancy. But the story of this drug extends well beyond the straightforward bladder infection, and its role in modern medicine is expanding in ways that matter if you or someone you know deals with recurring or hard-to-treat UTIs.
How It Works
Most antibiotics attack bacteria by disrupting protein production or DNA replication. Fosfomycin takes a different route entirely. It blocks an enzyme called MurA, which catalyzes the very first step in building the bacterial cell wall. Without that step, the bacterium cannot assemble peptidoglycan, the structural mesh that keeps it from bursting. Because fosfomycin hits such an early and unique target, bacteria that have developed resistance to other antibiotic classes often remain fully susceptible to it.1PubMed Central. Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance The drug is bactericidal, meaning it kills bacteria outright rather than just slowing their growth, and it does so with very low toxicity to human cells.2PubMed Central. Fosfomycin: Mechanism and Resistance
The “tromethamine” part of the name refers to the salt form used in oral tablets and granules. An older calcium salt formulation exists but is rarely used now because the tromethamine version absorbs better. Bioavailability of the tromethamine salt runs roughly 33% to 44%, and some calculations based on how much drug shows up in urine put the figure even higher, around 58%.3PubMed Central. Fosfomycin: Pharmacological, Clinical and Future Perspectives – Section: Pharmacokinetics of Fosfomycin That distinction matters because fosfomycin reaches especially high concentrations in urine, which is exactly where you want it for a urinary tract infection. The drug is not metabolized by the liver; it passes through largely unchanged and concentrates in the bladder.
The Single-Dose Treatment for Uncomplicated UTIs
The headline feature of fosfomycin tromethamine is the dosing: one sachet of 3 grams dissolved in water, taken once. For a straightforward bladder infection in a woman, that single dose produces cure rates comparable to a full week of nitrofurantoin or trimethoprim-sulfamethoxazole, according to comparative trials.4PubMed. Single-dose treatment of acute cystitis with fosfomycin tromethamine One older head-to-head trial found that a single 3-gram dose of fosfomycin matched a 7-day nitrofurantoin course for both bacterial clearance and symptom relief.5Clinical Therapeutics. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection
A larger and more recent randomized trial from 2018, however, added some nuance. In that study, about 70% of women taking 5 days of nitrofurantoin had sustained clinical resolution at 28 days, compared with about 58% of women who received a single dose of fosfomycin, a statistically significant gap of 12 percentage points favoring nitrofurantoin.6JAMA. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women So fosfomycin still works well for most women with an uncomplicated bladder infection, but nitrofurantoin appears to have a modest edge when you measure outcomes a month later. This is worth knowing because your doctor might choose one over the other depending on whether convenience or marginal efficacy matters more in your situation. For many patients, a single dose that clears the infection and avoids a full week of pills is preferable, even if there is a slightly higher chance of needing a follow-up visit.
Activity Against Drug-Resistant Bacteria
This is where fosfomycin really earns its keep. Many urinary pathogens now produce extended-spectrum beta-lactamases (ESBLs), enzymes that chew through common antibiotics like amoxicillin and many cephalosporins. Fosfomycin’s completely different mechanism means ESBL-producing bacteria are usually still vulnerable. In laboratory testing of hundreds of ESBL-producing E. coli and Klebsiella strains, fosfomycin showed very high activity across the board.7PubMed Central. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures
The picture is not uniform across all species, though. A study of ESBL-producing uropathogens from three Veterans Affairs facilities found that overall resistance to fosfomycin was about 20%, but that number masked a sharp split between bacterial types. Among ESBL-producing E. coli, only about 4% were resistant, while among Klebsiella species, resistance was 46%.8PubMed Central. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients The practical takeaway: if your urine culture grows ESBL-producing E. coli, fosfomycin is likely to work. If it grows Klebsiella, there is a meaningful chance it won’t, and your doctor should check the susceptibility report before prescribing.
Use During Pregnancy
UTIs are common during pregnancy, and the list of antibiotics considered safe for pregnant women is short. Fosfomycin is classified as acceptable for use in pregnancy by multiple guidelines, and the evidence supports it. A systematic review and meta-analysis comparing single-dose fosfomycin tromethamine against other antibiotics found comparable clinical and microbiological resolution in both pregnant and non-pregnant women with uncomplicated UTIs, as well as in pregnant women with asymptomatic bacteriuria. No serious fosfomycin-related adverse events were reported, and the most common side effects were mild gastrointestinal symptoms.9PubMed. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and meta-analysis
A study focused on bacterial susceptibility in pregnant women specifically found that about 89% of urinary pathogens were sensitive to fosfomycin, with E. coli being the dominant cause of infection.10PubMed Central. Bacterial sensitivity to fosfomycin in pregnant women with urinary infection The single-dose convenience is particularly appealing during pregnancy, where adherence to longer courses can be challenging and minimizing fetal antibiotic exposure is a reasonable goal.
Recurrent UTIs and Multi-Dose Regimens
For people plagued by UTIs that keep coming back, fosfomycin is increasingly used in ways that go beyond the single-dose model. A multicenter open-label study that gave three doses of fosfomycin tromethamine (one dose every other day) found strong results for uncomplicated cystitis, with a clinical efficacy rate around 95% at day 15. For recurrent lower UTIs, the rate was about 77%, and for complicated lower UTIs it dropped to about 63%.11BMJ Open. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study These numbers suggest that the three-dose approach gets closer to matching standard multi-day antibiotics for trickier infections.
For prevention of recurrent UTIs, some guidelines recommend a 3-gram dose of fosfomycin every 10 days as long-term prophylaxis. But pharmacokinetic data suggest that such a long interval between doses leads to low drug levels that could encourage resistance. A more intensive schedule of 3 grams every 72 hours appears to maintain adequate concentrations in both blood and urine to reliably suppress E. coli.12PubMed Central. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection A separate analysis found that a once-weekly 3-gram dose was non-inferior to a fluoroquinolone for preventing recurrences in women.13Journal of Antimicrobial Chemotherapy. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection The optimal interval is still being refined, but the trend is toward dosing more frequently than once every 10 days for patients with truly recurrent infections.
Prostatitis and Male UTIs
Treating prostate infections is famously difficult because most antibiotics struggle to penetrate prostatic tissue. Fosfomycin, somewhat unusually, reaches therapeutic concentrations in the prostate and maintains a high prostate-to-blood ratio for up to 17 hours after an oral dose.14PubMed Central. Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli This makes it one of the few oral options for prostatitis caused by multidrug-resistant bacteria, a clinical scenario where the alternative is often weeks of intravenous antibiotics.
A study of chronic bacterial prostatitis treated with oral fosfomycin found that 82% of patients were cured at the end of therapy, and about 73% remained cured at 6-month follow-up.15Journal of Antimicrobial Chemotherapy. Oral fosfomycin for the treatment of chronic bacterial prostatitis The regimen typically involves a loading phase of 3 grams daily for a week, then 3 grams every 48 hours for a total course of 6 to 12 weeks. That is a much longer commitment than the single-dose UTI treatment, but it is still an oral drug you take at home rather than an IV drip at a hospital.16PubMed Central. Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations
Side Effects and Tolerability
Fosfomycin’s safety profile is one of its strongest selling points. The most common side effects are gastrointestinal: diarrhea, nausea, and stomach discomfort.17PubMed Central. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database For a single dose, these tend to be mild and self-limiting. When fosfomycin is used in repeated doses, diarrhea becomes more relevant. A phase I study comparing a daily dosing schedule to an every-other-day schedule found that people on the daily regimen had significantly more diarrhea-free days disrupted: about 61% of days diarrhea-free with daily dosing versus 77% with every-other-day dosing.18PubMed Central. Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants Serious adverse events are rare across both short and long-term use.
Fosfomycin does not cause the tendon damage associated with fluoroquinolones, does not carry the pulmonary fibrosis risk of long-term nitrofurantoin, and does not produce the allergic reactions common with penicillins. For patients with multiple drug allergies or those who have had bad reactions to standard UTI antibiotics, fosfomycin is often the most practical remaining option.
Combination Therapy for Serious Infections
Beyond simple UTIs, fosfomycin is being explored as a partner drug in combination regimens for severe infections, especially those caused by multidrug-resistant organisms. The logic is straightforward: when one antibiotic struggles to kill a resistant bug on its own, pairing it with a drug that attacks through a completely different mechanism can produce synergy, where the combined effect exceeds what either drug achieves alone.
Laboratory testing of fosfomycin paired with various antibiotics against bloodstream isolates from resistant gram-negative bacteria found synergy most frequently with beta-lactam combinations. Fosfomycin plus piperacillin-tazobactam showed synergy in about a third of tests, and fosfomycin with ceftazidime-avibactam showed similar rates. Importantly, no antagonism was seen with any combination tested.19PubMed. Evaluation of in vitro activity of fosfomycin, and synergy in combination, in Gram-negative bloodstream infection isolates in a UK teaching hospital Against carbapenemase-producing Klebsiella, the synergy rates with carbapenems were particularly impressive, reaching about 70% or higher when fosfomycin was combined with imipenem, meropenem, or doripenem.20PubMed. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates These are infections that often have few remaining treatment options, so a drug that makes existing antibiotics work better fills a genuinely important gap.
Its Role in Antibiotic Stewardship
One of the quieter but consequential uses of fosfomycin is as a “step-down” drug, meaning you switch to it after an initial course of a more powerful intravenous antibiotic. This matters because carbapenems, the heavy-duty IV antibiotics used for resistant infections, are a precious resource. The more they are used, the faster resistance to them spreads. A randomized controlled trial found that switching patients with complicated UTIs caused by resistant bacteria from IV carbapenems to oral fosfomycin produced comparable outcomes and significantly shortened hospital stays.21PubMed. Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infections: A randomized controlled trial
The value here is twofold: you get patients home sooner, and you preserve carbapenems for the situations where nothing else works. Fosfomycin fits this role because its activity extends to resistant gram-positives like MRSA and vancomycin-resistant enterococci in addition to resistant gram-negatives, making it useful across a broad range of hospital-acquired infections.22PubMed Central. Fosfomycin in antimicrobial stewardship programs
How Resistance Develops
No discussion of an antibiotic is complete without asking how bacteria fight back. Fosfomycin resistance happens through two main routes. The first involves the cellular doorways that fosfomycin uses to enter bacteria. The drug hitches a ride through transport proteins called GlpT and UhpT. Mutations that break or delete the genes for these transporters effectively lock fosfomycin out. A Canadian surveillance study spanning 15 years found that about 63% of fosfomycin-resistant E. coli isolates that lacked another resistance mechanism had mutations disabling one or more of these transport genes. None of the susceptible isolates had such mutations.23JAC-Antimicrobial Resistance. Mechanisms of fosfomycin resistance observed in clinical isolates of Escherichia coli from Canada: CANWARD 2007–2022 Similar findings appear across multiple studies, with mutations in the uhpA, uhpB, uhpC, uhpT, and glpT genes consistently showing up in resistant clinical isolates.24PubMed Central. Novel Chromosomal Mutations Responsible for Fosfomycin Resistance in Escherichia coli
The second route is enzymatic destruction. Bacteria can produce enzymes from the FosA family that chemically modify fosfomycin by attaching a glutathione molecule to it, rendering it inactive.25PubMed Central. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene What makes this concerning is that the genes for these enzymes can sit on plasmids, mobile genetic elements that bacteria swap between species like trading cards. Researchers have identified a growing list of FosA variants carried on transferable plasmids in E. coli, meaning resistance could spread horizontally to otherwise susceptible populations.26PubMed Central. Identification of FosA8, a Plasmid-Encoded Fosfomycin Resistance Determinant from Escherichia coli, and Its Origin in Leclercia adecarboxylata Plasmid-mediated fosA genes have been documented in isolates from France and elsewhere in Europe, raising concerns that fosfomycin resistance could accelerate as the drug is used more widely.27Emerging Infectious Diseases. Emergence of Plasmid-Mediated Fosfomycin-Resistance Genes among Escherichia coli Isolates, France
There is some good news amid these concerns. Lab-generated resistance mutations tend to come with a fitness cost to bacteria, making resistant strains less competitive in the body than their susceptible counterparts.28PubMed Central. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli And because the single-dose regimen for uncomplicated UTIs produces a brief, intense drug exposure rather than a prolonged low-level one, it may exert less selection pressure for resistance than multi-day courses of other antibiotics. Still, the growing use of fosfomycin for recurrent and complicated infections, which require longer courses, makes resistance surveillance important.
Biofilm Activity
Bacteria living in biofilms, the slimy communities that coat urinary catheters and other surfaces, are notoriously harder to kill than free-floating bacteria. Fosfomycin has demonstrated an ability to penetrate mature biofilms, killing more than 96% of viable E. coli bacteria within catheter-surface biofilms in one study, though it did not completely sterilize the surface.29Pathogens and Disease. Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection This property gives fosfomycin an advantage over many antibiotics that struggle to reach bacteria embedded in biofilm, and it partly explains why the drug can be useful for catheter-associated infections and chronic prostatitis where biofilms play a role.
Pediatric Use
Fosfomycin is sometimes used for UTIs in children, though experience in this age group remains limited compared to adults. Current data are reassuring on safety. A multicentre retrospective audit of fosfomycin use in Australian children and adolescents found clinical cure in 93% of cases, with only 2% experiencing drug-related side effects, both gastrointestinal and both resolved when the drug was stopped. Dosing was typically adjusted by age: 1 gram for children under a year old, 2 grams for those aged 1 to 12, and the standard 3-gram adult dose for adolescents over 12.30Journal of Antimicrobial Chemotherapy. A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents The primary indication in pediatrics is community-acquired lower UTIs, though there is growing interest in using fosfomycin for infections caused by multidrug-resistant organisms in children who have run out of other oral options.31PubMed Central. Fosfomycin in the pediatric setting: Evidence and potential indications
Dosing Considerations in Kidney Disease
Because fosfomycin is cleared almost entirely by the kidneys, impaired kidney function changes how the drug behaves. For the single-dose treatment of an uncomplicated UTI, this rarely matters much: the drug concentrates in urine regardless, and one dose is one dose. But for patients receiving repeated doses, particularly those in intensive care on kidney replacement therapy, dosing needs careful adjustment. Pharmacokinetic studies in critically ill patients on dialysis found that fosfomycin is removed to a significant degree during dialysis sessions. This means the dose should be timed or replenished after a dialysis session to maintain adequate drug levels.32Journal of Antimicrobial Chemotherapy. Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy Modeling work suggests that daily intravenous doses of 12 to 24 grams are plausible for critically ill patients on various forms of kidney replacement therapy, but the specifics depend heavily on the type and intensity of dialysis.33PubMed Central. Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy These are hospital-level decisions, not something the average outpatient needs to worry about, but they illustrate how a drug with a simple one-dose outpatient profile can become pharmacologically complex in sicker patients.
Effects on Gut Flora
Any antibiotic you swallow passes through your gut and can alter the bacteria living there. Fosfomycin is no exception, but the collateral damage appears modest compared to broader-spectrum agents. A controlled study in healthy volunteers given fosfomycin daily for 28 days found that while E. coli counts in stool dropped dramatically, overall bacterial counts remained relatively stable. No significant increases in staphylococci or Candida were seen, though Klebsiella-Enterobacter counts rose as E. coli declined, a common competitive rebound effect. The main clinical consequence was softer stools rather than any overgrowth of dangerous organisms. For the typical single-dose UTI treatment, the effects on gut flora are even more transient. This relatively light footprint on the microbiome is another reason fosfomycin is favored as a stewardship-friendly antibiotic: it does less collateral ecological damage than many alternatives.